Hereditary Cancer Screening

DSC’s Comprehensive Cancer Test Kit for clinicians is the first Comprehensive Cancer Risk Assessment designed to determine the risk of developing up to eight different types of cancer. When armed with this critical genetic information, physicians are able to successfully create strategic treatment plans based on the patient’s personal risk in order to reduce their chances of developing cancer. Our laboratory translates cutting-edge scientific discoveries into customized treatments.

The same technologies that are improving the discovery of therapeutic molecules for cancer are being used by our lab to assist in the screening, diagnosis, classification of cancer patients, and the optimization of drug therapy.

Our Cancer Screening Laboratory customizes healthcare by featuring a CLIA certified molecular laboratory that provides the highest quality molecular testing services to medical practitioners. Our highly experienced pathologists and molecular geneticists are leaders in their field with specialist knowledge and expertise. They can help predict disease risk and determine how patients might respond to certain treatments.

What is genetic testing for cancer risk?

Genetic testing for cancer risk is an assessment tool that can predict the likelihood of an individual developing cancer in his or her lifetime.

  • Genetic testing can help predict the likelihood that a person will develop a disease, including some types of cancer.
  • Genetic testing is a personal decision with many factors to consider.
  • Anyone who decides to undergo genetic testing should receive genetic counseling before and after the test is performed.
*Not everyone with a cancer-related gene will develop cancer.


Who may be at risk for developing hereditary cancer?

1. People with a family history of cancer
Those with three or more relatives on the same side of the family with the same or related forms of cancer

2. People whose family history includes early onset of cancer
Those with two or more relatives diagnosed with cancer at an early age

3. People who have family members with cancer at multiple sites
Those with two or more types of cancer occurring in the same relative

94 Genes Tested in a Full Panel!
We have higher quality scores and therefore lower error rates.
We sequence homopolymers accurately, while others have an inherent problem
in sequencing those regions.
We measure the accuracy of every base, while others rely on stacks of reads and a reference.
Our sequencing approach is more sensitive and produces
In summary, our results are at least 10 times more reliable
in comparison with other companies’ results.
All analyses include insertions and deletions (INDELS) which are paramount to a proper diagnosis. Also, Sanger Sequencing (gold standard) is done as a confirmation/check on all dubious mutations found through the sequencing process.